serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for SERPINE1

Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
No VIP available CA VA
rs1799889 NC_000007.13:g.100769711A>G, NC_000007.14:g.101126430A>G, NG_013213.1:g.4333A>G, NM_000602.4:c.-816A>G, XM_005250392.1:c.-816A>G, rs36228268, rs57255496
A > G
No VIP available CA VA
rs2227631 NC_000007.13:g.100769538A>G, NC_000007.14:g.101126257A>G, NG_013213.1:g.4160A>G, NM_000602.4:c.-989A>G, XM_005250392.1:c.-989A>G, rs17252074, rs36228270, rs3807512, rs61391252
A > G
No VIP available No Clinical Annotations available VA
rs2227684 NC_000007.13:g.100776931G>A, NC_000007.14:g.101133650G>A, NG_013213.1:g.11553G>A, NM_000602.4:c.701-45G>A, XM_005250392.1:c.656-45G>A, rs17135259, rs57441338
G > A
No VIP available CA VA
rs6092 NC_000007.13:g.100771717G>A, NC_000007.14:g.101128436G>A, NG_013213.1:g.6339G>A, NM_000602.4:c.43G>A, NP_000593.1:p.Ala15Thr, XM_005250392.1:c.43G>A, XP_005250449.1:p.Ala15Thr, rs11553531, rs52825313
G > A
No VIP available No Clinical Annotations available VA
rs7242 NC_000007.13:g.100781445T>G, NC_000007.14:g.101138164T>G, NG_013213.1:g.16067T>G, NM_000602.4:c.*722T>G, XM_005250392.1:c.*722T>G, rs11553536, rs1799866, rs3167785, rs59555200
T > G
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147


Alternate Names:  PAI1; PLANH1; plasminogen activator inhibitor, type I
Alternate Symbols:  PAI
PharmGKB Accession Id: PA261


Cytogenetic Location: chr7 : q21.3 - q22.1
GP mRNA Boundary: chr7 : 100770370 - 100782547
GP Gene Boundary: chr7 : 100760370 - 100785547
Strand: plus


UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available

Curated Information ?

Publications related to SERPINE1: 4

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014. Lopez-Lopez Elixabet, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008. French Deborah, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response. Pharmacogenetics and genomics. 2008. Tsai Shih-Jen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction of fibrinolysis and prothrombotic risk factors in neonates, infants and children with and without thromboembolism and underlying cardiac disease. a prospective study. Thrombosis research. 2001. Nowak-Göttl U, et al. PubMed


NCBI Gene:
UCSC Genome Browser:
RefSeq RNA:
RefSeq Protein:
RefSeq DNA:
Comparative Toxicogenomics Database:
HumanCyc Gene:

Common Searches